一、前言日本同位素协会医学、药学部加速器核医学利用专门委员会制订了关于(1)医疗设施或医学研究设施内加速器生产的超短半衰期核素的临床应用指针;(2)关于医院内加速器放射性药剂的指针;(3)关于医院加速器放射性药剂的临床使用指针;(4)加速器核医学利用专门委员会批准为成熟技术的放射性药剂的基准和临床应用指针。作为药剂必须在临床前阶段验证其“有效性”和“安全性”,但医院内制剂的放射 I. INTRODUCTION The Japan Isotope Institute of Medicine and Pharmacy Department of Accelerator Nuclear Medicine developed a clinical application guideline on (1) the clinical application of very short half-life nuclides for accelerators in medical facilities or medical research facilities; (2) (3) a pointer to the clinical use of hospital accelerator radiopharmaceuticals; and (4) guidelines for the benchmark and clinical use of radiopharmaceuticals approved by the Commission for Accelerated Nuclear Medicine as a mature technique. As a pharmaceutical agent, its “effectiveness” and “safety” must be verified at the preclinical stage, but radiation in the hospital’s preparation